E1A specifically enhances sensitivity to topoisomerase IIα targeting anticancer drug by up-regulating the promoter activity

Molecular Cancer Research

Volumn 3, Issue 5, 2005, Pages 271-275

  Zhou, Zhichao ^a   Guan, Hui ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; E1A PROTEIN; ETOPOSIDE; LUCIFERASE;

ARTICLE; CANCER THERAPY; CELL DIVISION; CONTROLLED STUDY; EWING SARCOMA; GENE ACTIVITY; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; UPREGULATION; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENOVIRUS E1A PROTEINS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; HUMANS; PROMOTER REGIONS (GENETICS); UP-REGULATION;

EID: 18544380681     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-04-0179     Document Type: Article

References (23)

1. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-75.
2. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65:635-92.
3. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992;31:205-13.
4. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 1989;41:223-41.
5. Zwelling LA, Hinds M, Chan D, et al. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem 1989;264:16411-20.
6. Malonne H, Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs 1997;8:811-22.
7. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES. Transfection of human topoisomerase IIα into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 1996;319:307-13.
8. Zhou Z, Jia SF, Hung MC, Kleinerman ES. E1A sensitizes HER-2/nue-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 2001;61:3394-8.
9. Zhou R, Jia S-F, Zhou Z, Wang Y, Bucana CD, Kleinerman ES. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther 2002;9:407-13.
10. Chen Y-NP, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonist. Proc Natl Acad Sci U S A 1999;96:4325-9.
11. Lafeur EA, Worth LL, Jia S-F, Owen-Schaub LB, Kleinerman ES. Interleukin-12 activates the Fas promoter expression and influencing the metastatic potential of human osteosarcoma cells [abstract]. Proc AACR 2002;43:706.
12. Kalma Y, Marash L, Lamed Y, Ginsberg D. Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2. Oncogene 2001;20:1379-87.
13. Beck WT, Mo YY, Bhat UG. Cytotoxic signalling by inhibitors of DNA topoisomerase II. Biochem Soc Trans 2001;29:702-3.
14. 2-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanism of tumor suppression. Cancer Res 2002;62:346-50.
15. Yu D, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A 1990;87:4499-503.
16. Guan H, Jia S-F, Zhou Z, Stewart J, Kleinerman ES. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances Taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 2005;11:2008-17.
17. Scheltema JM, Romijn JC, van Steenbrugge GJ, Beck WT, Schroder FH, Mickisch GH. Decreased levels of topoisomerase IIα in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol 1997;123:546-54.
18. Zhou Z, Zwelling LA, Kawakami Y, et al. Adenovirus-mediated human topoisomerase II-α gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 59:4618-24.
19. Hortobagyi GN, Hung MC, Lopez-Berestein G. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu. Hum Gene Ther 1998;9:1775-98.
20. Graham FL, Prevec L. Manipulation of adenovirus vector. Gene transfer and expression protocol. In: Murray EJ, editor. Methods in molecular biology. Vol. 7. Clifton (NJ): Humana Press; 1991. p. 109-28.
21. Jordan JP, Hand CM, Markowitz RS, Black P. Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay. J Neurooncol 1992;14:19-35.
22. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol Cell Biol 1997;17:389-97.
23. Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human fas promoter requires NF-κB p50-p65 recruitment. Mol Cell Biol 1999;19:1098-108.